Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines

International Journal of Cancer

Volumn 125, Issue 10, 2009, Pages 2288-2295

  Singh, Shailesh ^a   Singh, Rajesh ^a   Singh, Udai P ^b   Rai, Shesh N ^a   Novakovic, Kristian R ^a   Chung, Leland W K ^c   Didier, Peter J ^d   Grizzle, William E ^e   Lillard Jr , James W ^a,f  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TULANE UNIVERSITY   (United States)

^e University of Alabama at Birmingham   (United States)

^f MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

Chemokine; Prostate cancer; Tissue expression

Indexed keywords

CHEMOKINE RECEPTOR CXCR5; COLLAGENASE 3; INTERSTITIAL COLLAGENASE; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3;

ARTICLE; CANCER CELL; CELL STRAIN LNCAP; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO SELECTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION;

CELL ADHESION; CELL MOVEMENT; CHEMOKINE CXCL13; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, CXCR5; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 70349852547     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24574     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2008;58:71-96.
2. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. [comment]. CA Cancer J Clin 1999;49:8-31.
3. Nicolson GL. Paracrine and autocrine growth mechanisms in tumor metastasis to specific sites with particular emphasis on brain and lung metastasis. Cancer Metastasis Rev 1993;12:325-343
4. Roh KJ, Kim DJ, Kim DW, Wang JM. Chemokines and their role in tumor growth and metastasis. J Bone Joint Surg Br 1998;80:1005-1008
5. Hanahan D, Weinberg RA. The hallmark of cancer. Cell 2000;100:57-70.
6. Sternlicht MD, Bergers G. Matrix metalloproteinases as emerging tragets in anti-cancer therapy: status and prospect. Emerg Ther Targets 2000;4:609-633
7. Liotta LA, Tryggnason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980;284:67-68 (Pubitemid 10098769)
8. Mignatti P, Robbins E, Rifkin DB. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell 1986;47:487-498 (Pubitemid 17215340)
9. Stetler-Stevenson WG, Hewitt R, Corcoran M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol 1996;7:147-154 (Pubitemid 26179261)
10. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 1998;185:256-261 (Pubitemid 28320046)
11. Lampert K, Machein U, Machein RL, Conca W, Peter HH, Volk B. Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors. Am J Pathol 1998;153:429-437 (Pubitemid 28373654)
12. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516. (Pubitemid 33096184)
13. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121-127 (Pubitemid 30398626)
14. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-56 (Pubitemid 32225831)
15. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002;62:1832-1837 (Pubitemid 34408510)
16. Singh S, Singh UP, Grizzle WE, Lillard JW. CXCL12-CXCR4 interactions modulates prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest 2004;84:1666-1676 (Pubitemid 39600573)
17. Engl T, Relja B, Blumenberg C, Muller I, Ringel EM, Beecken W-D, Jonas D, Blaheta RA. Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Life Sci 2006;78:1784-1793 (Pubitemid 43295576)
18. Wang J, Shiozawa Y, Wang J, Wang Y, Jung Y, Pienta KJ, Mehra R, Loberg R, Taichman RS. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem 2008;283:4283-4294
19. Shulby SA, Dolloff NG, Stearns ME, Meucci O, Fatatis A. CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res 2004;64:4693-4698 (Pubitemid 38924507)
20. Vaday GG, Peehl DM, Kadam PA, Lawrence DM. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 2006;66:124-134 (Pubitemid 43191234)
21. Heresi GA, Wang J, Taichman R, Chirinos JA, Regalado JJ, Lichtstein DM, Rosenblatt JD. Expression of the chemokine receptor CCR7 in prostate cancer presenting with generalized lymphadenopathy: report of a case, review of the literature, and analysis of chemokine receptor expression. Urol Oncol 2005;23:261-267 (Pubitemid 40961938)
22. Singh S, Singh UP, Stiles JK, Grizzle WE, Lillard JW. Expression and functional role of CCR9 in prostate cancer cell migration and invasion. Clin Cancer Res 2004;10:8743-8750 (Pubitemid 40053444)
23. Meijer J, Zeelenberg IS, Sipos B, Roos E. The CXCR5 chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver. Cancer Res 2006;66:9576-9582 (Pubitemid 44623656)
24. Wedel SA, Raditchev IN, Jones J, Juengel E, Engl T, Jonas D, Blaheta RA. CXC chemokine mRNA expression as a potential diagnostic tool in prostate cancer. Mol Med Rep 2008;1:257-262
25. Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). Biometrika 1965;52:591-611.
26. Rai SN, Lensing S, Boyett J, Phipps S. On the analysis of Messy longitudinal data from a study of pediatric cancer patients. Proceedings of the Joint Statistical Meetings 2004, Biometrics Section, Toronto, ON; 427-433
27. Ebisuno Y, Tanaka T, Kanemitsu N, Kanda H, Yamaguchi K, Kaisho T, Akira S, Miyasaka M. Cutting edge: the B cell chemokine CXC chemokine ligand 13/B lymphocyte chemoattractant is expressed in the high endothelial venules of lymph nodes and Peyer's patches and affects B cell trafficking across high endothelial venules. J Immunol 2003;171:1654-2546 (Pubitemid 36966445)
28. Airoldi I, Cocco C, Morandi F, Prigione I, Pistoia V. CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow. Cancer Immunol Immunother 2008;57:541-548 (Pubitemid 351170537)
29. Woo SU, Bae JW, Kim HG, Choi SH, Kang DH, Lee JB, Koo BW. Correlation between the in vitro ATP-based chemosensitivity assay and HER2/neu expression in women with breast cancer. J Intl Med Res 2007;35:753-761
30. Spano JP, Andre F, Morat L, Sabatier L, Besse B, Combadiere C, Deterre P, Martin A, Azorin J, Valeyre D, Khayat D, Le Chevalier T, et al. Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol 2004;15:613-617 (Pubitemid 38559598)
31. Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, Karplus R, Beider K, Avniel S, Kasem S, Galun E, Peled A. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J 2004;18:1240-1242 (Pubitemid 39561563)
32. Petrek M, Kolek V, Szotkowska J, du Bois RM. CC and C chemokine expression in pulmonary sarcoidosis. Eur Respir J 2002;20:1206-1212
33. Kahari VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 1999;31:34-45. (Pubitemid 29134483)
34. Still K, Robson CN, Autzen P, Robinson MC, Hamdy FC. Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in human benign and malignant prostatic tissue. Prostate 2000;42:18-25. (Pubitemid 30004871)
35. Arai J, Yasukawa M, Yakushijin Y, Miyazaki T, Fujita S. Stromal cells in lymph nodes attract B-lymphoma cells via production of stromal cell-derived factor-1. Eur J Haematol 2000;64:323-332 (Pubitemid 30307704)
36. Wright DE, Bowman EP, Wagers AJ, Butcher EC, Weissman IL. Hematopoietic stem cells are uniquely selective in their migratory response to chemokines. J Exp Med 2002;195:1145-1154
37. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Brikedal- Hansen B, DeCarlo A, Engler JA. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993;4:197-250.
38. Woessner JFJ. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-2154
39. Birkedal-Hansen B, Pavelic ZP, Gulckman JL, Stombrook P, Li YQ, Stetler-Stevenson WG. MMP and TIMP gene expression in head and neck squamous cell carcinomas and adjacent tissues. Oral Dis 2000;6:376-382
40. Okada T, Ngo VN, Ekland EH, Forster R, Lipp M, Littman DR, Cyster JG. Chemokine requirements for B cell entry to lymph nodes and Peyer's patches. J Exp Med 2002;196:65-75. (Pubitemid 34747312)
41. Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-a correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 2004;90:2312-2316 (Pubitemid 38961893)
42. Singh S, Singh R, Sharma P, Singh UP, Rai SN, Chung LWK, Cooper CR, Novakovic KR, Grizzle WE, Lillard JW, Jr. Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell migration, integrin clustering and cell adhesion. Cancer Lett 2009, in press.
43. Ebert LM, Schaerli P, Moser B. Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues. Mol Immunol 2005;42:799-809. (Pubitemid 40489029)
44. Finke D, Acha-Orbea H, Mattis A, Lipp M, Kraehenbuhl J. CD4+CD3- cells induce Peyer's patch development: role of alpha4-beta1 integrin activation by CXCR5. Immunity 2002;17:363-373
45. Lu TT, Cyster JG. Integrin-mediated long-term B cell retention in the splenic marginal zone. Science 2002;297:409-412 (Pubitemid 34790772)
46. Kanemitsu N, Ebisuno Y, Tanaka T, Otani K, Hayasaka H, Kaisho T, Akira S, Katagiri K, Kinashi T, Fujita N, Tsuruo T, Miyasaka M. CXCL13 is an arrest chemokine for B cells in high endothelial venules. Blood 2005;106:2613-2618 (Pubitemid 41510731)